View ValuationSawai Group Holdings 향후 성장Future 기준 점검 3/6Sawai Group Holdings (는) 각각 연간 30.5% 및 5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.7% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 11% 로 예상됩니다.핵심 정보30.5%이익 성장률29.67%EPS 성장률Pharmaceuticals 이익 성장18.9%매출 성장률5.0%향후 자기자본이익률10.99%애널리스트 커버리지Good마지막 업데이트13 Feb 2026최근 향후 성장 업데이트공고 • May 12+ 1 more updateSawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the first half year ending September 2023 and fiscal year ending March 31, 2024. For the first half year, the company expects sales of JPY 105,700 million, operating profit of JPY 7,000 million, profit attributable to owners of parent of JPY 5,100 million and basic earnings per share of JPY 116.46.For the full year, the company expects sales of JPY 217,200 million, operating profit of JPY 15,100 million, profit attributable to owners of parent of JPY 11,300 million and basic earnings per share of JPY 258.04.공고 • Feb 13+ 1 more updateSawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects sales to be JPY 207,000 million. Operating profit to be JPY 21,400 million. Profit attributable to owners of parent to be JPY 17,700 million. Basic earnings per share to be JPY 404.19.모든 업데이트 보기Recent updates공고 • Aug 20Sawai Group Holdings Co., Ltd. to Report Q2, 2027 Results on Nov 13, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2027 results at 3:00 PM, Tokyo Standard Time on Nov 13, 2026공고 • Jun 01Sawai Group Holdings Co., Ltd. to Report Q1, 2027 Results on Aug 10, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 10, 2026공고 • May 15Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026.공고 • Feb 20Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on May 15, 2026공고 • Nov 27Sawai Group Holdings Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 13, 2026공고 • Oct 21Sawai Pharmaceutical Co., Ltd. Announces Settlement of LawsuitSawai Group Holdings Co., Ltd. announced that Sawai Pharmaceutical Co., Ltd. has reached a settlement dated October 20, 2025, with Asahi Kasei Pharma Corporation regarding a patent infringement lawsuit concerning TERIPARATIDE for Subcutaneous Injection 56.5ug. Sawai Pharmaceutical had been requested by Asahi Kasei Pharma to cease the manufacturing and sale of its generic teriparatide product and to pay damages for patent infringement, based on the process patent (Patent No. 6025881) related to Teribone 56.5 ug for subcutaneous injection. Sawai Pharmaceutical's claim was not upheld, and on September 26, 2024, The Osaka District Court issued an order preventing the manufacture and sale of the product using the patented method in question and requiring the payment of damages. An appeal was filed with the Intellectual Property High Court of Japan (hereinafter the "IP High Court") against this ruling; however, after carefully considering the overall terms of the settlement, Sawai Pharmaceutical determined that resolving the matter through settlement was a reasonable course of action and reached an agreement accordingly. Sawai Pharmaceutical paid Asahi Kasei Pharma JPY 4 billion yen as a settlement, and Asahi Kasei Pharma waived any other claims against Sawai Pharmaceutical. Details of the settlement will not be disclosed due to confidentiality obligations contained in the settlement terms.공고 • Aug 19Sawai Group Holdings Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2026 results at 3:00 PM, Tokyo Standard Time on Nov 14, 2025공고 • Jul 02Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025. Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025.공고 • Jun 02Sawai Group Holdings Co., Ltd. to Report Q1, 2026 Results on Aug 12, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2026 results at 1:00 PM, Tokyo Standard Time on Aug 12, 2025공고 • May 14Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025.공고 • Mar 01Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2025 Results on May 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2025 results on May 14, 2025공고 • Nov 30Sawai Group Holdings Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025공고 • Aug 28Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024공고 • Jun 25Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.Sawai Group Holdings Co., Ltd. (TSE:4887) announces a share repurchase program. Under the program, the company will repurchase up to 6,900,000 shares, representing 15.75% of its share capital, for ¥33,000 million. The purpose of the program is capital efficiency improvement and improve shareholder return. The program will expire on March 31, 2025. As of May 31, 2024, the company had 43,802,973 shares in issue (excluding treasury stock) and 366 shares in treasury.공고 • Jun 06Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2025 results on Aug 09, 2024공고 • May 15Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024.공고 • Apr 03Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).Bora Pharmaceuticals Co., LTD. (TWSE:6472) agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) for approximately $210 million on January 16, 2024.The closing of the transaction is subject to customary regulatory approvals, United States antitrust authorities and in accordance with other laws and regulations. As of January 17, 2024, Trading value of equity interest $160 million and $8 million upon the achievement of the conditions of Earnout, and the equivalent of $40 million value from Upsher-Smith separately through dividends or a repurchase of SAH shares held by Sawai Group. The expected closing date of the transaction is March 17, 2024. BDO Taiwan CPA Firm acted as accountant to Bora Pharmaceuticals. Stifel Financial Corp. (NYSE:SF) acted financial advisor to Sawai Group Holdings Co., Ltd. Andrew L. Bab, Rafael Kariyev, Peter F.G. Schuur, Henry Lebowitz, Paul D. Rubin, Melissa Runsten, Kim T. Le, M. Natasha Labovitz, Sidney P. Levinson of Debevoise & Plimpton LLP and Katten Muchin Rosenman LLP both acted as legal advisor to Sawai Group Holdings Co., Ltd.Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) on April 1, 2024.공고 • Mar 02Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q4, 2024 results on May 13, 2024공고 • Nov 27Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024공고 • Nov 11+ 1 more updateSawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2024. For the year-end, the company expects to pay dividend of JPY 65.00 per share against JPY 65.00 per share paid a year ago.공고 • Aug 27Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023공고 • May 31Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023공고 • May 12+ 1 more updateSawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the first half year ending September 2023 and fiscal year ending March 31, 2024. For the first half year, the company expects sales of JPY 105,700 million, operating profit of JPY 7,000 million, profit attributable to owners of parent of JPY 5,100 million and basic earnings per share of JPY 116.46.For the full year, the company expects sales of JPY 217,200 million, operating profit of JPY 15,100 million, profit attributable to owners of parent of JPY 11,300 million and basic earnings per share of JPY 258.04.공고 • May 11Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023.공고 • Feb 13+ 1 more updateSawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects sales to be JPY 207,000 million. Operating profit to be JPY 21,400 million. Profit attributable to owners of parent to be JPY 17,700 million. Basic earnings per share to be JPY 404.19.공고 • Nov 30Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023이익 및 매출 성장 예측OTCPK:SWGH.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2028229,55122,2878,23230,91573/31/2027216,64420,0354,24728,12993/31/2026203,76414,963-3,61321,302912/31/2025200,680-1,250-5,99820,288N/A9/30/2025199,997309-4,33619,023N/A6/30/2025194,20713,942-6,91216,334N/A3/31/2025189,0242,17333727,851N/A12/31/2024184,01415,636-5,56519,321N/A9/30/2024177,33816,552-4,92019,972N/A6/30/2024168,20117,756-3,76718,698N/A3/31/2024176,86217,218-1,50023,149N/A12/31/2023185,30917,709-1,56223,849N/A9/30/2023191,32414,545-18,59118,350N/A6/30/2023205,10212,513-23,34314,446N/A3/31/2023200,34412,667-14,11513,026N/A12/31/2022196,280-33,307-18,37111,249N/A9/30/2022192,928-31,031-1,59217,320N/A6/30/2022191,561-30,9044,40124,856N/A3/31/2022193,816-28,26910,96634,310N/A12/31/2021193,14910,83518,19841,875N/A9/30/2021194,34910,96213,80940,262N/A6/30/2021193,76313,1779,91234,797N/A3/31/2021187,21912,34010,73331,857N/A12/31/2020184,96819,34812,66429,573N/A9/30/2020182,22819,10714,77228,534N/A6/30/2020179,34518,31313,51931,840N/A3/31/2020182,53719,27912,08330,256N/A12/31/2019186,61019,89124,26041,627N/A9/30/2019186,03019,831N/A59,020N/A6/30/2019186,17720,554N/A43,615N/A3/31/2019184,34119,376N/A42,924N/A12/31/2018189,52616,777N/AN/AN/A9/30/2018186,10215,743N/A26,361N/A6/30/2018179,72014,619N/AN/AN/A3/31/2018168,06814,017N/A28,472N/A12/31/2017147,59216,268N/AN/AN/A9/30/2017137,77016,140N/A10,997N/A6/30/2017133,12616,213N/AN/AN/A3/31/2017132,42815,914N/A20,628N/A12/31/2016132,49016,840N/AN/AN/A9/30/2016129,95017,222N/A24,152N/A6/30/2016127,05416,421N/AN/AN/A3/31/2016123,49217,155N/A19,975N/A12/31/2015117,64116,353N/AN/AN/A9/30/2015114,21015,554N/A14,914N/A6/30/2015109,71615,706N/AN/AN/A3/31/2015105,45414,053N/A12,112N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SWGH.F 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: SWGH.F (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: SWGH.F 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: SWGH.F 의 수익(연간 5%)이 US 시장(연간 12.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SWGH.F 의 수익(연간 5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SWGH.F의 자본 수익률은 3년 후 11%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/02/14 06:14종가2025/11/17 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sawai Group Holdings Co., Ltd.는 16명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Atsushi SekiBarclaysRitsuo WatanabeBofA Global ResearchHidemaru YamaguchiCitigroup Inc13명의 분석가 더 보기
공고 • May 12+ 1 more updateSawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the first half year ending September 2023 and fiscal year ending March 31, 2024. For the first half year, the company expects sales of JPY 105,700 million, operating profit of JPY 7,000 million, profit attributable to owners of parent of JPY 5,100 million and basic earnings per share of JPY 116.46.For the full year, the company expects sales of JPY 217,200 million, operating profit of JPY 15,100 million, profit attributable to owners of parent of JPY 11,300 million and basic earnings per share of JPY 258.04.
공고 • Feb 13+ 1 more updateSawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects sales to be JPY 207,000 million. Operating profit to be JPY 21,400 million. Profit attributable to owners of parent to be JPY 17,700 million. Basic earnings per share to be JPY 404.19.
공고 • Aug 20Sawai Group Holdings Co., Ltd. to Report Q2, 2027 Results on Nov 13, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2027 results at 3:00 PM, Tokyo Standard Time on Nov 13, 2026
공고 • Jun 01Sawai Group Holdings Co., Ltd. to Report Q1, 2027 Results on Aug 10, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 10, 2026
공고 • May 15Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2026.
공고 • Feb 20Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2026 results at 3:00 PM, Tokyo Standard Time on May 15, 2026
공고 • Nov 27Sawai Group Holdings Co., Ltd. to Report Q3, 2026 Results on Feb 13, 2026Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 13, 2026
공고 • Oct 21Sawai Pharmaceutical Co., Ltd. Announces Settlement of LawsuitSawai Group Holdings Co., Ltd. announced that Sawai Pharmaceutical Co., Ltd. has reached a settlement dated October 20, 2025, with Asahi Kasei Pharma Corporation regarding a patent infringement lawsuit concerning TERIPARATIDE for Subcutaneous Injection 56.5ug. Sawai Pharmaceutical had been requested by Asahi Kasei Pharma to cease the manufacturing and sale of its generic teriparatide product and to pay damages for patent infringement, based on the process patent (Patent No. 6025881) related to Teribone 56.5 ug for subcutaneous injection. Sawai Pharmaceutical's claim was not upheld, and on September 26, 2024, The Osaka District Court issued an order preventing the manufacture and sale of the product using the patented method in question and requiring the payment of damages. An appeal was filed with the Intellectual Property High Court of Japan (hereinafter the "IP High Court") against this ruling; however, after carefully considering the overall terms of the settlement, Sawai Pharmaceutical determined that resolving the matter through settlement was a reasonable course of action and reached an agreement accordingly. Sawai Pharmaceutical paid Asahi Kasei Pharma JPY 4 billion yen as a settlement, and Asahi Kasei Pharma waived any other claims against Sawai Pharmaceutical. Details of the settlement will not be disclosed due to confidentiality obligations contained in the settlement terms.
공고 • Aug 19Sawai Group Holdings Co., Ltd. to Report Q2, 2026 Results on Nov 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2026 results at 3:00 PM, Tokyo Standard Time on Nov 14, 2025
공고 • Jul 02Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506).Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025. The expected completion of the transaction is June 30, 2025. Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025.
공고 • Jun 02Sawai Group Holdings Co., Ltd. to Report Q1, 2026 Results on Aug 12, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2026 results at 1:00 PM, Tokyo Standard Time on Aug 12, 2025
공고 • May 14Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2025.
공고 • Mar 01Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2025 Results on May 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report fiscal year 2025 results on May 14, 2025
공고 • Nov 30Sawai Group Holdings Co., Ltd. to Report Q3, 2025 Results on Feb 14, 2025Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2025 results on Feb 14, 2025
공고 • Aug 28Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024
공고 • Jun 25Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.Sawai Group Holdings Co., Ltd. (TSE:4887) announces a share repurchase program. Under the program, the company will repurchase up to 6,900,000 shares, representing 15.75% of its share capital, for ¥33,000 million. The purpose of the program is capital efficiency improvement and improve shareholder return. The program will expire on March 31, 2025. As of May 31, 2024, the company had 43,802,973 shares in issue (excluding treasury stock) and 366 shares in treasury.
공고 • Jun 06Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2025 results on Aug 09, 2024
공고 • May 15Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024.
공고 • Apr 03Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).Bora Pharmaceuticals Co., LTD. (TWSE:6472) agreed to acquire Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) for approximately $210 million on January 16, 2024.The closing of the transaction is subject to customary regulatory approvals, United States antitrust authorities and in accordance with other laws and regulations. As of January 17, 2024, Trading value of equity interest $160 million and $8 million upon the achievement of the conditions of Earnout, and the equivalent of $40 million value from Upsher-Smith separately through dividends or a repurchase of SAH shares held by Sawai Group. The expected closing date of the transaction is March 17, 2024. BDO Taiwan CPA Firm acted as accountant to Bora Pharmaceuticals. Stifel Financial Corp. (NYSE:SF) acted financial advisor to Sawai Group Holdings Co., Ltd. Andrew L. Bab, Rafael Kariyev, Peter F.G. Schuur, Henry Lebowitz, Paul D. Rubin, Melissa Runsten, Kim T. Le, M. Natasha Labovitz, Sidney P. Levinson of Debevoise & Plimpton LLP and Katten Muchin Rosenman LLP both acted as legal advisor to Sawai Group Holdings Co., Ltd.Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887) on April 1, 2024.
공고 • Mar 02Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q4, 2024 results on May 13, 2024
공고 • Nov 27Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2024 results on Feb 14, 2024
공고 • Nov 11+ 1 more updateSawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided dividend guidance for the fiscal year ending March 31, 2024. For the year-end, the company expects to pay dividend of JPY 65.00 per share against JPY 65.00 per share paid a year ago.
공고 • Aug 27Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023
공고 • May 31Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023
공고 • May 12+ 1 more updateSawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024Sawai Group Holdings Co., Ltd. provided consolidated earnings guidance for the first half year ending September 2023 and fiscal year ending March 31, 2024. For the first half year, the company expects sales of JPY 105,700 million, operating profit of JPY 7,000 million, profit attributable to owners of parent of JPY 5,100 million and basic earnings per share of JPY 116.46.For the full year, the company expects sales of JPY 217,200 million, operating profit of JPY 15,100 million, profit attributable to owners of parent of JPY 11,300 million and basic earnings per share of JPY 258.04.
공고 • May 11Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023.
공고 • Feb 13+ 1 more updateSawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023Sawai Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2023. For the year, the company expects sales to be JPY 207,000 million. Operating profit to be JPY 21,400 million. Profit attributable to owners of parent to be JPY 17,700 million. Basic earnings per share to be JPY 404.19.
공고 • Nov 30Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023Sawai Group Holdings Co., Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023